## PATENT COOPERATION TREATY

# **PCT**

## INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

(Chapter II of the Patent Cooperation Treaty)

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference					
	FOR FURTHER ACTION	See Form PC	TT/IPEA/416		
PU0418-PCT	International filing date (day/n	month(sear)	Priority date (day/month/year)		
International application No.			02-04-2004		
PCT/SE2005/000467	31-03-2005		02-04-2004		
International Patent Classification (IPC)	or national classification and IPC	C			
See Supplemental Box					
Author					
Applicant	mana an at al				
GE HEALTCARE BIO-SCIE	NCES AB et al				
<ol> <li>This report is the international preliminary examination report, established by this International Preliminary Examining Authority under Article 35 and transmitted to the applicant according to Article 36.</li> </ol>					
2. This REPORT consists of a total	of 7 sheets, incl	luding this cover	sheet.		
<ol> <li>This report is also accompanied t</li> </ol>	oy ANNEXES, comprising:				
			C. H		
	t and to the International Burea				
and/or sheets	s containing rectifications autho	wings which have orized by this Aut	been amended and are the basis of this report hority (see Rule 70.16 and Section 607 of the		
	ve Instructions).	hich this Authori	ty considers contain an amendment that goes		
beyond the	lisclosure in the international ap	pplication as filed	, as indicated in item 4 of Box No. I and the		
Supplements					
b. (sent to the Internati	ional Bureau only) a total of (in	dicate type and n	umber of electronic carrier(s))		
,			and/or tables related thereto, in electronic		
form only, as indicated in the Supplemental Box Relating to Sequence Listing (see Section 802 of the					
Administrative Instr	uctions).				
4. This report contains indications					
Box No. I Basis	of the report				
Box No. II Priori	ty				
Box No. III Non-e	stablishment of opinion with re	egard to novelty, i	nventive step and industrial applicability		
Box No. IV Lack	of unity of invention				
Box No. V Reaso	Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial				
	eability; citations and explanation in documents cited	ous supporting su	eit statement		
		mlication			
2000.110.11.					
Box No. VIII Certain observations on the international application					
Date of submission of the demand	Da	ate of completion	of this report		
Date of submission of the damand					
05-10-2005	0:	3-07-2006	i		
Name and mailing address of the IPEA/		uthorized officer			
Patent- och registreringsverket					
BOX 5055 8-102 42 STOCKHOLM	-	and Walt-	n/Ple		
Facsimile No. +46 8 667 72 88		Jens Waltin/Els Telephone No. +46 8 782 25 00			

Form PCT/IPEA/409 (cover sheet) (April 2005)

International application No.

PCT/SE2005/000467

#### Supplemental Box

In case the space in any of the preceding boxes is not sufficient.

Continuation of: Cover sheet

International patent classification (IPC)

**B01D 15/10** (2006.01)

**B01D 15/32** (2006.01)

**BOID 15/36** (2006.01)

**B01D 15/38** (2006.01)

CO7K 1/16 (2006.01)

Form PCT/IPEA/409 (Supplemental Box) (April 2005)

International application No.

PCT/SE2005/000467

Box	No. I	Basis of the report						
t.	1. With regard to the language, this report is based on:							
the international application in the language in which it was filed								
	a translation of the international application into							
		which is the language of a translation furnished for the purposes of:						
		international search (Rules 12.3(a) and 23.1(b))						
		publication of the international application (Rule 12.4(a))						
		international preliminary examination (Rules 55.2(a) and/or 55.3(a))						
2.	furnish	With regard to the elements of the international application, this report is based on (replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report):						
	$\boxtimes$	the international application as originally filed/furnished						
		the description:						
		pages as originally filed/furnished						
		pages* received by this Authority on						
		pages* received by this Authority on						
		the claims:						
		pages as originally filed/furnished						
		pages* as amended (together with any statement) under Article 19						
		pages* received by this Authority on						
	_	pages* received by this Authority on						
	Ш	the drawings:						
		pages as originally filed/furnished						
		pages* received by this Authority on						
		pages* received by this Authority on						
		a sequence listing and/or any related table(s) - see Supplemental Box Relating to Sequence Listing.						
3.		The amendments have resulted in the cancellation of:						
		the description, pages						
		the claims, Nos.						
		the drawings, sheets/figs						
		the sequence listing (specify):						
		any table(s) related to the sequence listing (specify):						
4.		This report has been established as if (some of) the amendments annexed to this report and listed below had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).						
		the description, pages						
		the claims, Nos.						
		the drawings, sheets/figs						
		the sequence listing (specify):  any table(s) related to the sequence listing (specify):						
•	If item	a 4 applies, some or all of those sheets may be marked "superseded."						
For		IPEA/409 (Box No. 1) (April 2005)						

International application No.

PCT/SE2005/000467

	soned statement un tions and explanat		5(2) with regard to novelty, inventive step or in ng such statement	ıdustrial applicability;
1. Statement				
Novelty (N)	)	Claims	5-7, 12-28	YES
		Claims	1-4. 8-11	NO NO
Inventive st	ep (IS)	Claims	5-7. 12-14	YES
		Claims	1-4. 8-11. 15-28	NO NO
Industrial a	pplicability (IA)	Claims	1-28	YES
		Claims		NO NO

2. Citations and explanations (Rule 70.7)

#### Cited prior art:

We refer to the following document, cited in the International Search Report:

D1: US 3 869 436 A

D1 relates to the fractionating of plasma proteins by ion-exchange chromatography. The method comprises:

- precipitating the globulins in the plasma with poly(ethylene glycol) (PEG),
- centrifuging out all of the precipitate from the remaining solution,
- dissolving the precipitate in sodium acetate-acetic acid,
- adsorbing the globulins from the dissolved precipitate on a cation-exchanger,
- precipitating the eluate with PEG,
- dissolving the precipitate in phosphate buffer, and
- adsorbing the globulins from the dissolved precipitate on an anion-exchanger.

#### Novelty:

The method according to claims 1-4, 8 and 10-11 lacks novelty in view of D1.

The method according to claims 5-6 and 12-14 includes an affinity chromatography step and the method according to claim 7 comprises three steps. The process disclosed in D1, on the other hand, comprises two ion-exchange steps.

The method according to claims 5-7 and 12-14 is thus novel in view of D1.

. . . / . . .

International application No.

PCT/SE2005/000467

#### Supplemental Box

In case the space in any of the preceding boxes is not sufficient.

Continuation of: Box V

In the International search report, D1 was not considered relevant regarding novelty or inventive step with respect to claim 9. However, this opinion has been reassessed.

According to claim 9, the polyether is present in at least two steps. It appears from D1 (col. 3, line 7 - col. 4, line 32) that PEG is present in both the cation exchange step and in the anion exchange step. Thus, claim 9 lacks novelty in view of D1 as well.

#### Inventive step:

It is not considered obvious to a person skilled in the art to modify the process disclosed in D1 so as to arrive at the invention claimed in claims 5-7 or 12-14. Said claims thus present an inventive step.

The features of claims 15-17, regarding the design of the ion-exchange matrix, are known per se. They are considered to be merely some of several straightforward possibilities from which the skilled person would select, in accordance with circumstances, without the exercise of inventive skill, in order to solve the problem posed. Therefore, the invention according to claims 15-17 is considered to lack an inventive step.

The invention according to the independent claims 20 and 25 relates to a method for isolating an antibody compound from a liquid, comprising contacting the liquid, in the presence of a non-ionic polyether, with an ion-exchange chromatography matrix.

The method according to claim 20 differs from the subject matter of D1 in that the conductivity is specified to equivalent to 200 mM NaAc. NaAc is mentioned in D1 but the conductivity is not specified. However, this difference is not considered inventive. Thus, claim 20 and the dependent claims 21-24 lack an inventive step.

. . . / . . .

International application No.

PCT/SE2005/000467

#### Supplemental Box

In case the space in any of the preceding boxes is not sufficient. Continuation of:  $\ensuremath{\text{Box}}\xspace V$ 

In independent claim 25, the design of the ion-exchange matrix is specified. For the same reasons as set out above, in connection with claims 15-17, the subject matter of claims 25-27 is considered to lack an inventive step.

Claims 18-19 and 28 relate to kits with separate compartments intended for antibody isolation. Such kits are well-known to a person skilled in the art and this solution has already been applied for the same purpose in similar contexts. Therefore, the subject matter of claims 18-19 and 28 is not considered inventive.

#### Industrial applicability:

The claimed invention is considered to be industrially applicable.

Form PCT/IPEA/409 (Supplemental Box) (April 2005)

International application No.

PCT/SE2005/000467

Box No. VI	Cartain	defects in	the internationa	i annlication
DOX MO. VI	ı Certain	i uciecta in	the internations	i application

The following defects in the form or contents of the international application have been noted: In claims 7-9, it seems that the words "according to any one of the preceding steps" should be replaced by "according to any one of the preceding claims".